Advertisement
Advertisement
U.S. markets close in 50 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Dermata Therapeutics, Inc. (DRMA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6299-0.0094 (-1.47%)
As of 02:56PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.6393
Open0.6014
Bid0.6100 x 1200
Ask0.6299 x 1100
Day's Range0.6004 - 0.6600
52 Week Range0.4350 - 2.7320
Volume57,677
Avg. Volume195,138
Market Cap7.623M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DRMA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Dermata Therapeutics, Inc.
    Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
    Rating
    Fair Value
    Economic Moat
    24 days agoArgus Research
View more
  • InvestorPlace

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

    Good morning, trader! Rub that sleep out our your eyes because we’re going over the biggest pre-market stock movers for Thursday! Source: oneinchpunch/Shutterstock.com We’re still knee-deep in earnings seasons as many companies report results from the most recent quarter today. Let’s get into that news below!InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-Market Stock Movers: 10 Top Gainers Dermata Therapeutics (NASDAQ:DRMA) stock is soaring more than 31% alongside heavy tradi

  • Benzinga

    Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know

    Dermata Therapeutics Inc (NASDAQ: DRMA) has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal pharmacokinetics study before the End of Phase 2 meeting for its DMT310 acne program. The Company said it has already planned and budgeted to conduct both studies. The requests come as DMT310 has been used in clinical trials by over 170 patients exhibiting an acceptable safety and tolerability profile. Further, the FDA approved the Company to use

Advertisement
Advertisement